Our Omnichannel Maturity tool is designed for biopharmaceutical, healthcare technology, and wellness companies that are driven to develop integrated and customer-centric omnichannel experiences.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.